Infections

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Immune System Diseases

Rare Diseases

Skin Neoplasms

Communicable Diseases

Sarcoma

Acquired Immunodeficiency Syndrome

HIV Infections

Sarcoma, Kaposi

Opportunistic Infections

AIDS-Related Opportunistic Infections

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Neoplasms, Vascular Tissue

Soft Tissue Sarcoma

Anti-Infective Agents

All Drugs and Chemicals

HIV Protease Inhibitors

Protease Inhibitors

Nelfinavir

Anti-HIV Agents

Enzyme Inhibitors

Anti-Retroviral Agents

Antiviral Agents

Nelfinavir mesylate

To determine the effect of Viracept in combination with modified antiretroviral therapy on the outcome of cutaneous and mucosal Kaposi's Sarcoma (KS).

This is an open-label, randomized, pilot, Phase II study of the safety and efficacy of Viracept in combination with modified antiretroviral therapy as treatment in patients with cutaneous and mucosal KS. Patients will be randomized to modify (add or switch or initiate) their current antiretroviral therapy and will add Viracept or remain on their current background antiretroviral therapy for a 2 month period. Initially 20 patients will be randomized in a 2:1 ratio (i.e., 14 Viracept, 6 control) for a 2 month period. Response to therapy will be evaluated at the end of the 2 month control phase. At this point, patients who were initially assigned to the control arm will continue on open label Viracept for an additional 10 month period.

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

Agouron Pharmaceuticals

Syndrome

Immunologic Deficiency Syndromes

Kaposi Sarcoma

Ritonavir

Cytochrome P-450 CYP3A Inhibitors

Cytochrome P-450 Enzyme Inhibitors

To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.

The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma

Abbott

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3	NCT00002185	Sarcoma, Kaposi HIV Infections	Nelfinavir mesy...	13 Years -	NIH AIDS Clinical Trials Information Service
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma	NCT00002366	Sarcoma, Kaposi HIV Infections	Ritonavir	18 Years -	Abbott

Spots Global Cancer Trial Database for hiv protease inhibitors